Tissue plasminogen activator human

pkg of 10 μg, ≥400,000 IU/mg (activity expressed per mg of tPA)

Enzyme Commission number:
MDL number:


expressed in CHO cells


lyophilized powder

specific activity

≥400,000 IU/mg (activity expressed per mg of tPA)

mol wt

~70 kDa


pkg of 10 μg

storage temp.


Gene Information

human ... PLAT(5327)

Looking for similar products? Visit Product Comparison Guide


Tissue plasminogen activator has been used in a study to assess treatment risks of intracranial hemorrhage among patients with acute ischemic stroke. Tissue plasminogen activator has also been used in a study to investigate the successful treatment of early thrombosis of HeartWare left ventricular assist devices with intraventricular thrombolytics.

Physical form

Tissue Plasminogen Activator (tPA) is a protease of the S1 family (trypsin family) and is found in a wide variety of mammalian tissues, especially endothelial cells. tPA is secreted as a single chain precursor, which is cleaved to a two-chain form by plasmin. Supplied in the single chain form with a molecular weight of ~70 kDa.
Supplied as lyophilized powder containing 10 μg tPA lyophilized from a 100 μg/ml solution containing 1 M NH4HCO4 with 1% bovine serum albumin.


Exclamation mark

Signal Word


Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


UN 3077 9 / PGIII

WGK Germany


Abdallah Kamouh et al.
The Annals of thoracic surgery, 94(1), 281-283 (2012-06-28)
In the last few years, left ventricular assist devices (LVADs) have moved to the forefront in the management of patients with advanced heart failure. Pumps have gradually become smaller and more efficient and have clearly demonstrated survival benefits and improvement...
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator
Xian, Y., et al.
Journal of the American Medical Association, 307, 2600-2608 (2012)
Dan Huang et al.
Frontiers of medicine, 11(3), 410-422 (2017-07-09)
Aberrant expression of annexin A2-S100A10 heterotetramer (AIIt) associated with PML/RARα fusion protein causes lethal hyperfibrinolysis in acute promyelocytic leukemia (APL), but the mechanism is unclear. To facilitate the investigation of regulatory association between ANXA2 and promyelocytic leukemia/retinoic acid receptor a...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.